Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 3, 2009, Pages 638-644

  Zhang, Yi ^a   Thamer, Mae ^a   Cotter, Dennis J ^a   Kaufman, James ^b   Hernán, Miguel A ^c  

^a Medical Technology and Practice Patterns Institute   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; BIOLOGICAL MARKER; HEMOGLOBIN;

AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DRUG INDICATION; DRUG MEGADOSE; ELDERLY CARE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MORTALITY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SURVIVAL RATE; UNITED STATES; AGE; BLOOD; CHRONIC KIDNEY FAILURE; FEMALE; IRON DEFICIENCY ANEMIA; MALE; METABOLISM; RENAL REPLACEMENT THERAPY; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANEMIA, IRON-DEFICIENCY; BIOLOGICAL MARKERS; EPOETIN ALFA; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MODELS, STATISTICAL; RENAL DIALYSIS; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 66149151415     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05071008     Document Type: Article

References (23)

1. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1988
2. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006 (Pubitemid 44749317)
3. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12: 2465-2473, 2001 (Pubitemid 33021125)
4. Lowrie EG, Huang WH, Lew NL, Liu Y: The relative contribution of measured variables to death risk among hemodialysis patients. In: Death on Hemodialysis, edited by Friedman EA, Dordrecht, Kluwer Academic Publishers, 1994, pp 121-141
5. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10: 610-619, 1999 (Pubitemid 29117643)
6. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ: Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44: 866-876, 2004 (Pubitemid 39445919)
7. Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K, Owen WF: Anemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 8: 1921-1929, 1997
8. Strippoli GF, Tognoni G, Navaneethan SD, Nicolucci A, Craig JC: Haemoglobin targets: We were wrong, time to move on. Lancet 369: 346-350, 2007 (Pubitemid 46188478)
9. Busko M: Higher haemoglobin targets linked to increased mortality risk in CKD patients with anemia, February 5, 2007, Available at: http://www.medscape. com/viewarticle/551687. Accessed May 22, 2008
10. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74: 791-798, 2008
11. EPO & DPO Use by Provider, Figure 5.39. In: US Renal Data System, USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006. Available at: http://www.usrds.org/ 2006/pdf/05-clin-ind-prev-hlth-06.pdf. Accessed January 31, 2008
12. Henke M, Laszig R, Rube C, Schäfer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H: Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy. Lancet 362: 1255-1260, 2003
13. Leyland-Jones B; BEST investigators: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet 4: 459-460, 2003
14. Ifudu O, Mathew JJ, Mayers JD, Macey LJ, Brezsnyak W, Reydel C, McClendon E, Surgrue T, Rao S, Friedman EA: Severity of AIDS and response to EPO in uremia. Am J Kidney Dis 30: 28-35, 1997 (Pubitemid 27284371)
15. Frankenfield DL, Roman SH, Rocco MV, Bedinger MR, McClellan WM: Disparity in outcomes for adult Native American hemodialysis patients? Findings from the ESRD clinical performance measures project, 1996 to 1999. Kidney Int 65: 1426-1434, 2004
16. Hernán MA, Hernandez-Diaz S, Robins JM: A structural approach to selection bias. Epidemiology 15: 615-625, 2004
17. Robins JM, Hernán MA, Brumback B: Marginal structural models and causal inference in epidemiology. Epidemiology 11: 550-560, 2000
18. Hernán MA, Brumback B, Robins JM: Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11: 561-570, 2000 (Pubitemid 30660035)
19. Hernán MA, Brumback B, Robins JM: Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med 21: 1689-1709, 2002 (Pubitemid 34678901)
20. Cotter D, Zhang Y, Thamer M, Kaufman J, Hernán M: The effect of epoetin dose on hematocrit. Kidney Int 73: 347-353, 2008
21. Thamer M, Zhang Y, Kaufman J, Cotter D, Hernán MA: Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 297: 1667-1674, 2007 (Pubitemid 46631625)
22. Vaziri ND: Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol Hypertens 10: 633-637, 2001 (Pubitemid 32783813)
23. Bradbury BD, Wang O, Critchlow CW, Rothman KJ, Heagerty P, Keen M, Acquavella JF: Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis 51: 62-70, 2008 (Pubitemid 350296516)